| Title: | A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations |
| Authors: | Asahina, H. Browse this author |
| Yamazaki, K. Browse this author |
| Kinoshita, I. Browse this author |
| Sukoh, N. Browse this author |
| Harada, M. Browse this author |
| Yokouchi, H. Browse this author |
| Ishida, T. Browse this author |
| Ogura, S. Browse this author |
| Kojima, T. Browse this author |
| Okamoto, Y. Browse this author |
| Fujita, Y. Browse this author |
| Dosaka-akita, H. Browse this author |
| Isobe, H. Browse this author |
| Nishimura, M. Browse this author →KAKEN DB |
| Keywords: | gefitinib |
| non-small cell lung cancer (NSCLC) |
| epidermal growth factor receptor (EGFR) |
| mutation |
| first-line therapy |
| Issue Date: | 23-Oct-2006 |
| Publisher: | Nature Publishing Group |
| Journal Title: | British Journal of Cancer |
| Volume: | 95 |
| Issue: | 8 |
| Start Page: | 998 |
| End Page: | 1004 |
| Publisher DOI: | 10.1038/sj.bjc.6603393 |
| PMID: | 17047648 |
| Abstract: | Retrospective analysis has shown that activating mutations in exons 18-21 of the epidermal growth factor receptor (EGFR) gene are a predictor of response to gefitinib. We conducted a phase II trial to evaluate the efficacy and safety of gefitinib as first-line therapy for advanced non-small cell lung cancer (NSCLC) with EGFR mutations. Patients with stage IIIB or IV chemotherapy-naïve NSCLC with EGFR mutation were treated with 250 mg gefitinib daily. For mutational analysis, DNA was extracted from paraffin-embedded tissues and EGFR mutations were analysed by direct sequence of PCR products. Twenty (24%) of the 82 patients analysed had EGFR mutations (deletions in or near E746-A750, n=16; L858R, n=4). Sixteen patients were enrolled and treated with gefitinib. Twelve patients had objective response and response rate was 75% (95% CI, 48-93%). After a median follow-up of 12.7 months (range, 3.1-16.8 months), 10 patients demonstrated disease progression, with median progression-free survival of 8.9 months (95% CI, 6.7-11.1 months). The median overall survival time has not yet been reached. Most of the toxicities were mild. This study showed that gefitinib is very active and well tolerated as first-line therapy for advanced NSCLC with EGFR mutations. |
| Rights: | Nature Publishing Group, BRITISH JOURNAL OF CANCER, Vol. 95, issue 8, 2006, pp. 998-1004 |
| Relation: | http://npg.nature.com/npg/servlet/Content?data=xml/02_welcome.xml&style=xml/02_welcome.xsl |
| Type: | article (author version) |
| URI: | http://hdl.handle.net/2115/21810 |
| Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
